Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 893

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 893
---
s 
        per share amounts |         |   |     |      |         |   |
| Numerator:                                                       |     |                          |         |   |     |      |         |   |
| Net loss attributable to Kineta, Inc.                            |     |                        $ | (17,132 | ) |     |    $ | (14,099 | ) |
| Denominator:                                                     |     |                          |         |   |     |      |         |   |
| Weighted-average common shares outstanding, basic and diluted(1) |     |                          |  12,100 |   |     |      |  11,054 |   |
| Net loss per share, basic and diluted                            |     |                        $ |   (1.42 | ) |     |    $ |   (1.28 | ) |

F-127

#### KINETA, INC.Notes to Consolidated Financial Statements1.Included in the denominator for the years ended December 31, 2024 and 2023, were 286,000 and 628,000 weighted-average shares of common stock warrants, respectively, with exercise prices of $0.001 and $0.14 issued for nominal consideration.The following outstanding potentially dilutive common stock equivalents were excluded from the computation of diluted net loss per share as of the periods presented because including them would have been antidilutive:Years Ended December 31,20242023(in thousands)Warrants to purchase common stock2,5592,560Common stock options2,3311,975Vested restricted stock subject to recall5656Unvested restricted stock subject to repurchase—8Total4,9464,599Defined Contribution PlanThe Company sponsors a 401(k) Plan whereby all employees are eligible to participate in the 401(k) Plan after meeting certain eligibility requirements. Participants may elect to have a portion of their salary deferred and contributed to the 401(k) plan, subject to certain limitations. The Company provided matching contributions of $51,000 for the year ended December 31, 2024 and $115,000 for the year ended December 31, 2023.14. Related Party TransactionsStock PurchasesPursuant to the Settlement Agreement, on April 23, 2024, the Company issued 903,995 shares of its common stock to a company controlled by a director.During the year ended December 31, 2023, five members of the Company’s executive management purchased 43,000